Impact BioMedical Inc. (IBO) stock
Close on Oct 19, 2026Market cap $26.14MP/E –Yield –
Impact BioMedical Inc. reported revenue of $38.00K for the twelve months to Sep 30, 2026. At the latest close the market valued the company at $26.14M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $26.14M
- P/E ratio
- –
- Price to sales
- 688.02
- Price to book
- 2.58
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $38.00K
- Net income
- $1.61M
- EPS, diluted
- -$4.81
- Book value per share
- $1.18
- Diluted shares
- 9M
Trading
- Previous close
- $2.68
- Open
- $2.66
- Day's range
- $2.66 – $3.75
- Volume
- 47,952
- Average volume (20 days)
- 23,050
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | IBO | S&P 500 | Difference | IBO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +418.6% | +0.6% | +418.0 pts | ||
| 3 months | +571.1% | +3.4% | +567.7 pts | ||
| Year to date | +505.9% | +13.3% | +492.7 pts | ||
| 1 year | +413.3% | +16.6% | +396.7 pts |
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Press releases
Releases Impact BioMedical filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Update
- Update
About Impact BioMedical
Pharmaceutical Preparations
Impact BioMedical Inc. is a biotechnology company focused on the discovery, development, and patenting of science and technologies for human healthcare and wellness. The company operates in a single biotechnology business segment, targeting the prevention, inhibition, and treatment of neurological, oncological, and inflammatory conditions, as well as infectious diseases. Key product candidates and platforms include Linebacker for oncology and inflammatory disorders, Laetose as a low-glycemic alternative sugar formulation, Equivir for antiviral applications, and the 3F suite of functional fragrances. Its commercialization strategy centers on licensing and partnering with pharmaceutical, food, and consumer packaged goods companies.
Company profile, executives and historyImpact BioMedical stock: common questions
What is Impact BioMedical's stock price?
IBO closed at $3.06 on Oct 19, 2026, up 14.18% on the day.
What is Impact BioMedical's market cap?
Impact BioMedical was worth $26.14M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is IBO's P/E ratio?
Impact BioMedical lost money over fiscal 2025 (diluted EPS -$4.81), so it has no meaningful P/E ratio.
How much revenue does Impact BioMedical make?
Impact BioMedical reported revenue of $38.00K for the twelve months to Sep 30, 2026.
Does Impact BioMedical pay a dividend?
No. Impact BioMedical has not paid a cash dividend over the last twelve months.
How has IBO stock performed over the past year?
Including dividends, IBO returned +413.3% over the past year, against +16.6% for the S&P 500.
Who are Impact BioMedical's competitors?
Companies most similar to Impact BioMedical by business, industry and size include LNAI, CNBX, KZIA, NTHI, IFRX.
See a number that looks wrong?